leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 11:32:06 - browse：466

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Living organ donors deserve priority status for transplants

focus

WSS

Readout Newsletter: Zepbound, Valneva's vaccine, and more

How state and local governments are sidelining science

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Inside the rise of 'mukbang' eating videos

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

leisure time

leisure time

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

The thinking behind the controversial eating disorder chatbot Tessa

United colonoscopy coverage change 'may cost lives,' doctors say

Altering the blood type of lungs raises potential for universal organs for transplants

ChatGPT in medicine: STAT answers readers' burning questions

Reanimated hearts work just as well for transplants, study finds

BioMarin wins approval for gene therapy to treat hemophilia A

FDA approves first new drug developed for postpartum depression

As demand for Covid shots wanes, Moderna seeks its next success

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

focus

Cancer diagnosis changes perspective doctor, former hospital CEO

Study suggests Covid rebound is far more common with Paxlovid than without

How state and local governments are sidelining science

Biogen nominates mother of director’s child to replace him on board

Publishing genetic code of viruses could cause disaster

Biden administration plans revamp of organ transplant system

focus

focus

focus

leisure time